Your browser doesn't support javascript.
Red Blood Cell-Derived Nanoerythrosomes Mediated Efficient Delivery Of Mrna Vaccine Candidate Against COVID-19
Indian Journal of Hematology and Blood Transfusion ; 38(Supplement 1):S125, 2022.
Article in English | EMBASE | ID: covidwho-2175096
ABSTRACT

Introduction:

The COVID-19 pandemic has been a major public health concern throughout the world. Various ventures of vaccine candidates are being studied rigorously in this regard and one such candidate is the receptor binding domain (RBD) of spike protein which interacts with angiotensin converting enzyme 2 (ACE2) on the host cell's membrane. Exploiting this interaction, many scientists across the world attempted to develop mRNA vaccine against SARSCoV- 2. A major lacuna associated with mRNA vaccines is their delivery through a suitable carrier, especially given the stability issues associated with mRNA vaccines. Aims &

Objectives:

The aim of our research is to develop an efficient mode of delivery of the self-amplifying mRNA (saRNA) against COVID 19. We have developed small vesicles from erythrocyte ghosts, known as nanoerythrosomes, which are in the nanometre range and focussed on development of nanoerythrosomes for delivery of mRNA-based vaccines. Material(s) and Method(s) Nanoerythrosomes were prepared from erythrocytes using osmotic and ultrasonic frequency stress and loaded with saRNA vaccine candidate. Thereafter, the nanoerythrosomes were characterized using Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM) to confirm their homogeneity, integrity and size. The mRNA loaded nanoerythrosomes were used to deliver the mRNA in Vero E6 cells to evaluate its uptake. Result(s) The characterization of nanoerythrosomes using DLS and TEM revealed their size in the range of 100-200 nm. The delivery mediated by nanoerythrosomes was comparable to the Lipofectamine mediated uptake of saRNA indicating the excellent delivery efficacy of nanoerythrosomes. The added advantage of nanoerythrosomes mediated delivery is that they are rapidly taken up from blood by macrophages of the reticuloendothelial system (RES) that is present in liver, lung, and spleen. Thus the combination of saRNA and nanoerythrosomes can accelerate the uptake and antigen presentation in reticuloendothelial system and will provide an outstanding platform for the development of SARS-CoV2 vaccine. Conclusion(s) We developed a new approach to deliver mRNA vaccine candidates using nanoerythrosomes and successfully demonstrate its efficacy in vitro. This strategy can be further extended for the delivery of other vaccine candidates. (Figure Presented).
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Indian Journal of Hematology and Blood Transfusion Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Indian Journal of Hematology and Blood Transfusion Year: 2022 Document Type: Article